Peptipedia
ImmuneNot FDA ApprovedClinical Trials

Thymosin Alpha-1

Also known as Ta1, Zadaxin

A naturally occurring thymic peptide that enhances immune function.

Approved in 35+ countries - Not FDA approved in US
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1.6 mg twice weekly

Frequency

2-3x weekly

Duration

6-12 months for hepatitis

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1.6 mg twice weekly via Subcutaneous injection, 2-3x weekly. Dose range: 0.8-3.2 mg per dose. Duration: 6-12 months for hepatitis.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 2-3x weekly.

Mechanism of Action

Modulates T-cell function, enhances dendritic cell maturation, and promotes Th1 immune responses. Increases IL-2, interferon-alpha, and interferon-gamma.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in 35+ countries - Not FDA approved in US.

Side Effects & Safety

Important Warnings

  • Contraindicated in immunosuppressed transplant patients
Injection site reactions (most common)
mild fatigue
headache
rare allergic reactions

References

No references available.

Related Peptides

Browse all →
LL-37Immune

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

View profile
KPVImmune

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

View profile
ThymalinBioregulator

A thymic peptide complex utilized in Russia for immune enhancement and longevity support, developed through Professor Khavinson's bioregulator peptide research.

View profile